Ana S. Garcia Moreno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana S. Garcia Moreno has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aaron C. Olson
Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
1 shared publication - Alexander Q. Wixom
Mayo Clinic
1 shared publication - Daemiel L. Segamanasinghe
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
1 shared publication Daniel F. Gibbard
Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
1 shared publicationDouglas G. Brownfield
Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
1 shared publicationErik Jessen
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication
Latest Publications
- 23 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1149-1160
Preconditioning donor lungs with lung-derived exosomes mitigates ischemia-reperfusion injury in a warm ischemia porcine DCD model
- 23 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1149-1160
Preconditioning donor lungs with lung-derived exosomes mitigates ischemia-reperfusion injury in a warm ischemia porcine DCD model
- Open Access
- 1 June 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (6)
IL-17 signaling in primary sclerosing cholangitis patient-derived organoids
Background: The pathogenesis of primary sclerosing cholangitis (PSC) is unclear, although studies implicate IL-17A as an inflammatory mediator in this disease. However, a direct assessment of IL-17 signaling in PSC cholangiocytes is lacking. In this study, we aimed to investigate and characterize the response of PSC extrahepatic cholangiocyte organoids (ECO) to IL-17A stimulation. Methods: Cholangiocytes obtained from patients with PSC and without PSC by endoscopic retrograde cholangiography were cultured as ECO. The ECO were treated with vehicle or IL-17A and assessed by transcriptomics, secretome analysis, and genome sequencing. Results: Unsupervised clustering of all integrated single-cell RNA sequencing data identified 8 cholangiocyte clusters that did not differ between PSC and non-PSC ECO. However, PSC ECO cells demonstrated a robust response to IL-17 treatment, as noted by an increased number of differentially expressed genes by transcriptomics and more abundant chemokine and cytokine expression and secretion. After rigorous filtering, genome sequencing identified candidate somatic variants shared among PSC ECO from unrelated individuals. However, no candidate rare variants in genes regulating the IL-17 pathway were identified, but rare variants regulating the MAPK signaling pathway were present in all PSC ECO. Conclusions: PSC and non-PSC patient-derived ECO respond differently to IL-17 stimulation, implicating this pathway in the pathogenesis of PSC.
- 1 June 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (6)
Open AccessIL-17 signaling in primary sclerosing cholangitis patient-derived organoids
Background: The pathogenesis of primary sclerosing cholangitis (PSC) is unclear, although studies implicate IL-17A as an inflammatory mediator in this disease. However, a direct assessment of IL-17 signaling in PSC cholangiocytes is lacking. In this study, we aimed to investigate and characterize the response of PSC extrahepatic cholangiocyte organoids (ECO) to IL-17A stimulation. Methods: Cholangiocytes obtained from patients with PSC and without PSC by endoscopic retrograde cholangiography were cultured as ECO. The ECO were treated with vehicle or IL-17A and assessed by transcriptomics, secretome analysis, and genome sequencing. Results: Unsupervised clustering of all integrated single-cell RNA sequencing data identified 8 cholangiocyte clusters that did not differ between PSC and non-PSC ECO. However, PSC ECO cells demonstrated a robust response to IL-17 treatment, as noted by an increased number of differentially expressed genes by transcriptomics and more abundant chemokine and cytokine expression and secretion. After rigorous filtering, genome sequencing identified candidate somatic variants shared among PSC ECO from unrelated individuals. However, no candidate rare variants in genes regulating the IL-17 pathway were identified, but rare variants regulating the MAPK signaling pathway were present in all PSC ECO. Conclusions: PSC and non-PSC patient-derived ECO respond differently to IL-17 stimulation, implicating this pathway in the pathogenesis of PSC.